CN101277707A - 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物 - Google Patents

意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物 Download PDF

Info

Publication number
CN101277707A
CN101277707A CNA2006800250320A CN200680025032A CN101277707A CN 101277707 A CN101277707 A CN 101277707A CN A2006800250320 A CNA2006800250320 A CN A2006800250320A CN 200680025032 A CN200680025032 A CN 200680025032A CN 101277707 A CN101277707 A CN 101277707A
Authority
CN
China
Prior art keywords
cancer
tumor
pharmaceutical composition
carcinoma
arsenite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800250320A
Other languages
English (en)
Chinese (zh)
Inventor
S-B·李
Y·-J·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cominocs Co Ltd
Original Assignee
Komipharm International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Komipharm International Co Ltd filed Critical Komipharm International Co Ltd
Priority to CN201510064962.8A priority Critical patent/CN104758312A/zh
Publication of CN101277707A publication Critical patent/CN101277707A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)
CNA2006800250320A 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物 Pending CN101277707A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510064962.8A CN104758312A (zh) 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076071.9 2005-05-09
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510064962.8A Division CN104758312A (zh) 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物

Publications (1)

Publication Number Publication Date
CN101277707A true CN101277707A (zh) 2008-10-01

Family

ID=35197739

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800250320A Pending CN101277707A (zh) 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物
CN201510064962.8A Pending CN104758312A (zh) 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510064962.8A Pending CN104758312A (zh) 2005-05-09 2006-05-09 意欲用于治疗泌尿生殖器癌症及其转移的包含亚砷酸、其钠盐及其衍生物的药用组合物

Country Status (23)

Country Link
US (2) US20090011047A1 (https=)
EP (5) EP1721615A1 (https=)
JP (1) JP5026408B2 (https=)
KR (3) KR20160035101A (https=)
CN (2) CN101277707A (https=)
AR (1) AR054448A1 (https=)
AU (1) AU2006244767B2 (https=)
BR (1) BRPI0608716A2 (https=)
CA (3) CA2840609C (https=)
CY (2) CY1113475T1 (https=)
DK (2) DK1885380T3 (https=)
ES (2) ES2394264T3 (https=)
HU (1) HUE046029T2 (https=)
IL (3) IL187220A (https=)
LT (1) LT3067068T (https=)
PL (2) PL1885380T3 (https=)
PT (1) PT1885380E (https=)
RU (1) RU2401662C2 (https=)
SG (5) SG177983A1 (https=)
SI (2) SI3067068T1 (https=)
TW (5) TWI386214B (https=)
WO (1) WO2006121280A1 (https=)
ZA (1) ZA200710559B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753164A (zh) * 2009-09-10 2012-10-24 柯密纳克斯公司 靶向癌症干细胞的耐药性癌症疗法
CN112135608A (zh) * 2018-03-22 2020-12-25 科米药物国际澳大利亚公司 包含偏亚砷酸盐的药物组合物及其制造方法
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用
CN115243692A (zh) * 2020-02-16 2022-10-25 科微范国际澳大利亚私人有限公司 使用偏亚砷酸盐的治疗方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais
WO2011086137A1 (en) 2010-01-13 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
RU2602937C2 (ru) * 2011-01-11 2016-11-20 Универзитет Базель Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
EP3758686B1 (en) 2018-02-26 2024-11-06 R.P. Scherer Technologies, LLC Pharmaceutical dosage form for an emulsion of simethicone and loperamide
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020635A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 외용제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
CN116549741B (zh) * 2022-01-29 2025-04-11 中国科学院上海硅酸盐研究所 一种具有抑癌抗菌作用的表面改性镍钛合金材料及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
RU2035181C1 (ru) * 1994-02-18 1995-05-20 Тамара Васильевна Воробьева Средство для лечения лейкозов и способ лечения лейкозов
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
PT2475362T (pt) 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753164A (zh) * 2009-09-10 2012-10-24 柯密纳克斯公司 靶向癌症干细胞的耐药性癌症疗法
CN107412771A (zh) * 2009-09-10 2017-12-01 柯密纳克斯公司 靶向癌症干细胞的耐药性癌症疗法
CN112135608A (zh) * 2018-03-22 2020-12-25 科米药物国际澳大利亚公司 包含偏亚砷酸盐的药物组合物及其制造方法
CN115243692A (zh) * 2020-02-16 2022-10-25 科微范国际澳大利亚私人有限公司 使用偏亚砷酸盐的治疗方法
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用

Also Published As

Publication number Publication date
JP5026408B2 (ja) 2012-09-12
SI3067068T1 (sl) 2020-02-28
EP2361628A1 (en) 2011-08-31
IL187220A0 (en) 2008-02-09
SI1885380T1 (sl) 2013-01-31
PL1885380T3 (pl) 2013-02-28
TWI386214B (zh) 2013-02-21
SG10201602555WA (en) 2016-05-30
SG175633A1 (en) 2011-11-28
US20090011047A1 (en) 2009-01-08
TW201615200A (zh) 2016-05-01
LT3067068T (lt) 2019-12-10
SG10202100785PA (en) 2021-02-25
EP2762145A1 (en) 2014-08-06
IL229975A0 (en) 2014-01-30
TWI574692B (zh) 2017-03-21
CA2840609A1 (en) 2006-11-16
DK3067068T3 (da) 2019-11-18
KR101413731B1 (ko) 2014-07-10
ES2754372T3 (es) 2020-04-17
TW201500046A (zh) 2015-01-01
AU2006244767B2 (en) 2011-06-16
KR20160035101A (ko) 2016-03-30
IL244728A0 (en) 2016-04-21
TWI522105B (zh) 2016-02-21
CA2926846A1 (en) 2006-11-16
KR20150085122A (ko) 2015-07-22
KR20080030559A (ko) 2008-04-04
CY1113475T1 (el) 2016-06-22
SG177983A1 (en) 2012-02-28
TW201540306A (zh) 2015-11-01
PL3067068T3 (pl) 2020-08-10
EP3067068A1 (en) 2016-09-14
US11464859B2 (en) 2022-10-11
IL187220A (en) 2014-11-30
TWI539957B (zh) 2016-07-01
TW201302208A (zh) 2013-01-16
BRPI0608716A2 (pt) 2010-12-07
HUE046029T2 (hu) 2020-01-28
EP3067068B1 (en) 2019-08-14
RU2007145489A (ru) 2009-06-20
WO2006121280A1 (en) 2006-11-16
AR054448A1 (es) 2007-06-27
CY1122522T1 (el) 2021-01-27
ES2394264T3 (es) 2013-01-30
RU2401662C2 (ru) 2010-10-20
EP1885380B1 (en) 2012-07-11
SG10201405278SA (en) 2015-05-28
CA2840609C (en) 2016-08-16
IL229975A (en) 2017-12-31
CN104758312A (zh) 2015-07-08
JP2008546640A (ja) 2008-12-25
EP1885380A1 (en) 2008-02-13
CA2926846C (en) 2019-04-02
EP1721615A1 (en) 2006-11-15
ZA200710559B (en) 2008-10-29
TW200716144A (en) 2007-05-01
DK1885380T3 (da) 2012-10-22
CA2608035C (en) 2015-02-17
US20160199411A1 (en) 2016-07-14
EP1885380A4 (en) 2009-02-18
CA2608035A1 (en) 2006-11-16
AU2006244767A1 (en) 2006-11-16
HK1109736A1 (en) 2008-06-20
PT1885380E (pt) 2012-10-11

Similar Documents

Publication Publication Date Title
US11464859B2 (en) Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma
AU2011224052A1 (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
KR20140033522A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
HK1109736B (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
HK1096863A (en) Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
HK1161545A (en) Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma
HK1201043A1 (en) Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer
JP2009500416A (ja) カリケアマイシン−抗体複合体をゾスキダルと組み合わせて用いる癌患者の処置

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: COMINOCS CO.,LTD.

Free format text: FORMER OWNER: COMIFAM INTERNATIONAL CO., LTD.

Effective date: 20091120

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091120

Address after: Cayman Islands

Applicant after: Cominocs Co., Ltd

Address before: Gyeonggi Do, South Korea

Applicant before: Komipharm Internat Co., Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081001